Oculis will not pursue FDA approval for OCS-01, an eye drop for diabetic macular edema, after it failed to meet the primary ...
Ollin Biosciences, Inc. (Ollin), a clinical-stage biotech advancing best-in-disease therapies for vision-threatening diseases ...
Key Points Interested in Oculis Holding AG? Here are five stocks we like better. Oculis' Phase 3 DIAMOND trials of OCS-01 in ...
In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...
Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular-mediated inflammation, today announced that the first ...
Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...
Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary ...
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
The optic cup and macula of a 24-year-old female. Image is released to Wikimedia commons with patient consent. Imaged with a non-mydriatic fundus camera at Pacific University College of Optometry.
European commercialization introduces an additional aflibercept biosimilar option for major retinal indications, potentially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results